HKA surgical procedure aimed at treating Alzheimer’s disease is being tested in Hong Kong through a clinical trial led by researchers at the Chinese University of Hong Kong (CUHK). The procedure involves draining abnormal accumulations of two proteins in the brain and was initially developed by a mainland Chinese doctor in Hangzhou in 2018. It gained attention due to social media videos showcasing significant improvements in patients. However, concerns over safety and efficacy led China’s National Health Commission to ban its unregulated use in July 2025. CUHK researchers have since received approval for controlled trials, enrolling four patients, with one patient reportedly showing remarkable recovery. Dr. Tor Chiu, leading the study, hopes to assess the procedure’s effectiveness under scientific oversight and is currently seeking more participants.
Bias read (Center): The article presents information about a medical treatment for Alzheimer’s disease without overtly endorsing or criticizing any political stance. While it mentions regulatory actions by China’s National Health Commission, it does not frame these decisions as politically motivated or biased. The tone
